STLN Starling Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: STLN

Price (delayed)

$6.26

Market cap

$637.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$50,304.75

Enterprise value

$701.38M

?
Relative Growth: Rel. Growth: 63
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: 27
Relative Profitability: Rel. Profitability: 20
Highlights
The gross profit is up by 45% year-on-year and by 12% since the previous quarter
Starling Oncology's net income has increased by 38% YoY and by 12% QoQ
STLN's equity has dropped by 177% year-on-year and by 53% since the previous quarter
The quick ratio has contracted by 14% YoY
Sector: Healthcare
Industry: Medical Care Facilities
Website: https://starlingoncology.com

Key stats

What are the main financial stats of STLN

STLN stock price

How has the Starling Oncology stock price performed over time
Intraday
-0.95%
1 week
25.45%
1 month
0.16%
1 year
52.68%
YTD
75.84%
QTD
15.29%

Financial performance

How have Starling Oncology's revenue and profit performed over time
Revenue
$587.24M
Gross profit
$92.17M
Operating income
-$26.09M
Net income
-$40.83M
Gross margin
15.7%
Net margin
-7%
Starling Oncology's operating margin has soared by 60% YoY and by 27% from the previous quarter
The company's net margin has surged by 55% YoY and by 18% QoQ
The gross profit is up by 45% year-on-year and by 12% since the previous quarter
The operating income rose by 44% year-on-year and by 20% since the previous quarter

Price vs fundamentals

How does STLN's price correlate with its fundamentals

Growth

What is Starling Oncology's growth rate over time

Valuation

What is Starling Oncology stock price valuation
STLN P/E details
P/E
N/A
P/B
N/A
P/S
1.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.19
The EPS has grown by 5% YoY
STLN's equity has dropped by 177% year-on-year and by 53% since the previous quarter
The P/S is 57% more than the last 4 quarters average of 0.7 and 22% more than the 5-year quarterly average of 0.9
STLN's revenue is up by 38% year-on-year and by 8% since the previous quarter

Efficiency

How efficient is Starling Oncology business performance
The ROS has soared by 56% YoY and by 21% from the previous quarter
The ROA is up by 38% year-on-year and by 15% since the previous quarter
The company's return on invested capital rose by 32% YoY and by 13% QoQ

Dividends

What is STLN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for STLN.

Financial health

How did Starling Oncology financials performed over time
The total assets is 12% less than the total liabilities
Starling Oncology's total liabilities has increased by 20% YoY and by 10% from the previous quarter
The current ratio has contracted by 16% YoY and by 7% from the previous quarter
STLN's equity has dropped by 177% year-on-year and by 53% since the previous quarter
The debt to equity has soared by 64% YoY and by 35% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.